Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial

Table 3 Studied treatments

Drug	route	Authorized dose in product information*	Control group	Experimental group
Drug	route	Authorized dose in product information*	(full dose)	(reduced dose)
Adalimumab	SC	40 mg/2 weeks	40 mg/2 weeks	40 mg/3 weeks
Etanercept	SC	25 to 50 mg/3 to 7 days	25 mg/3 or 50 mg/7 days	50 mg/10 days
Golimumab	SC	50 mg/month	50 mg/month	50 mg/6 weeks
Infliximab	IV	5 mg/kg /6 to 8 weeks	5 mg/kg /6 to 8 weeks	3 mg/kg /8 weeks

ISSN: 1745-6215